Transcriptomic rationale for the synergy observed with dasatinib + bortezomib + dexamethasone in multiple myeloma
- نوع فایل : کتاب
- زبان : انگلیسی
- مؤلف : Edvan de Queiroz Crusoe & Patricia Maiso & Diego Fernandez-Lazaro & Laura San-Segundo & Mercedes Garayoa & Antonio Garcia-Gomez & Norma C. Gutierrez &
- چاپ و سال / کشور: 2011
Description
Despite the advantage observed with novel drugs such as bortezomib, thalidomide, or lenalidomide, multiple myeloma (MM) remains incurable and there is a clear need for new drugs or combinations based on the pathogenetic mechanism of MM. One of the proposed mechanisms in MM pathogenesis is the involvement of kinase molecules in the growth and survival of myelomatous cells. In this study, we have explored the optimal combination for dasatinib, a tyrosine kinase inhibitor, in MM cells. A clear synergistic effect was observed with the triple combination of dasatinib with bortezomib and dexamethasone which was evident even in the presence of bone marrow microenvironment. Experiments performed on freshly isolated patients’ cells also demonstrated potentiation of response in the triple as compared with the agents alone or in double combinations. Gene expression profiling experiments provided some clues on the transcriptional rationale underlying this potentiation, as the triple combination led to significant deregulation of genes involved in cell death, cell growth, proliferation, DNA replication, repair and recombination, and cell–cell signaling. Some of these results were further confirmed by apoptosis and cell cycle experiments and also by Western blot and PCR. These data provide the rationale for the use of this novel combination in MM patients.
Ann Hematol DOI 10.1007/s00277-011-1287-z Received: 13 February 2011 / Accepted: 17 June 2011
